SM compounds that antagonise cIAP1/2 have received attention as potential cancer therapeutics because cIAP1/2 are overexpressed in many cancer types and their elimination from cancer cells often induces TNF‐driven apoptosis (Vince et al, 2007; Bai et al, 2014; Fulda, 2015). Here, TNF is linked to cancer.